AstraZeneca Archives -

FDA grants fast review of AZ’s Brilinta to prevent recurring strokes

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce

FDA grants fast review of AZ’s Brilinta to prevent recurring strokes

https://pharmaphorum.com/news/az-grants-fast-review-of-astrazenecas-cardiovascular-diseases-drug-brilinta/

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

https://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

https://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaas-bavencio-in-first-line-bladder-cancer/

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

https://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

https://pharmaphorum.com/news/mercks-atr-cancer-drug-cleared-for-clinical-trials-after-phase-1-trial-success/

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies

After Celgene deal, BMS shoots up pharma market cap rankings

https://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/

AZ promises to deliver 400m doses of COVID-19 vaccine to Europe

AstraZeneca has followed through on its pledge to provide its COVID-19 vaccine at cost during the pandemic, saying

AZ promises to deliver 400m doses of COVID-19 vaccine to Europe

https://pharmaphorum.com/news/az-promises-to-deliver-400m-doses-of-covid-19-vaccine-to-europe/

Sanofi hands back gene therapies to Oxford Biomedica

Oxford Biomedica’s long-running alliance with Sanofi over a pair of gene therapies for ophthalmic diseases has come to

Sanofi hands back gene therapies to Oxford Biomedica

https://pharmaphorum.com/news/sanofi-hands-back-gene-therapies-to-oxford-biomedica/

AstraZeneca to lead workshop at Wearable Injectors and Connected Devices 2020

AstraZeneca to lead workshop at Wearable Injectors

AstraZeneca to lead workshop at Wearable Injectors and Connected Devices 2020

https://pharmaphorum.com/partner-content/astrazeneca-to-lead-workshop-at-wearable-injectors-and-connected-devices-2020/

Trending

AstraZeneca

Hello World

FDA grants fast review of AZ’s Brilinta to prevent recurring strokes

EU regulators approve AstraZeneca’s Lynparza in pancreatic cancer

FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success

After Celgene deal, BMS shoots up pharma market cap rankings

AZ promises to deliver 400m doses of COVID-19 vaccine to Europe

Sanofi hands back gene therapies to Oxford Biomedica

AstraZeneca to lead workshop at Wearable Injectors and Connected Devices 2020

Search

Advanced Search

Trending

AstraZeneca

Hello World